SPARK Co-Lab was based on the Stanford University SPARK program, established in 2007 with the goal of helping advance and translate new biomedical research discoveries into promising new treatments for patients. Since its founding, SPARK has advanced scores of new diagnostics and drugs to the clinic and commercial sectors, and educated hundreds of faculty, postdoctoral fellows, and students on the translational process. The majority of SPARK projects address the neglected areas of child and maternal health, global health, and orphan diseases. 

Researchers around the world face the common challenge of working out how to bridge the so-called “Valley of Death” between the discovery of an idea and its eventual commercial development and realisation. Most early-stage ideas are unlikely to attract interest or funding from industry until they have reached significant milestones, and will likely fail during development.​​

Programs based on the Stanford SPARK program provide a cost-effective model to help innovators and entrepreneurs mature their proof of concept and de-risk their ideas. By clearly defining their idea and the unmet need it targets, tackling obstacles and identifying key commercialisation milestones at an early stage, researchers are given a pathway to a license or follow on funding for their discovery, based on industry standards with industry-based guidance, mentoring and support.​​​​​​​​​

To find out more about the SPARK Program, ​click here.

Find out more about the SPARK program.​

The SPARK Approach authored by Stanford SPARK 
co-founders Daria Mochly-Rosen and Kevin Grimes.